Blue Note Therapeutics and Bixink Enter Licensing Agreement for attune™ and DreAMLand™, Prescription Digital Therapeutics for Mental Well-Being in Cancer Patients
In support of expanding access to cancer-specific digital therapeutics, Blue Note has entered into an exclusive licensing agreement with Bixink for the commercialization of attune™ and DreAMLand™ in South Korea.
New Study Finds Cancer-Related Anxiety and Depression are Costing Medicare $5B Annually
Blue Note Therapeutics announces findings of new study highlighting the financial impacts of cancer-related anxiety and depression in Medicare beneficiaries.
Blue Note Therapeutics to Present Health Economic Data at NCCN 2022 Annual Conference
Blue Note Therapeutics will share new findings on the incremental healthcare costs of anxiety and depression in Medicare patients living with cancer. This is the largest and most comprehensive assessment of its kind.
Cancer-related distress, which can be defined as any unpleasant feeling, emotion, or experience that affects a cancer patient’s quality of life or ability to cope with cancer diagnosis and treatment, affects millions of people. Fewer than half of those who experience cancer-related distress have access to the mental health care they need to find relief. Blue Note Therapeutics is working to close this gap.Learn more